Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial
about
Galantamine for Alzheimer's disease and mild cognitive impairmentGalantamine for Alzheimer's diseaseCurrent pharmacologic options for patients with Alzheimer's diseaseSystematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase InhibitorsTreatment guidelines for Alzheimer's disease: redefining perceptions in primary care.The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial.Early Diagnosis and Treatment of Dementia Presenting as Transient Global Amnesia in a 76-Year-Old Man.Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease.The Effects of an Uninterrupted Switch from Donepezil to Galantamine without Dose Titration on Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease.Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.A searchable cross-platform gene expression database reveals connections between drug treatments and disease.Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease : A systematic review across modalitiesEfficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimenA systematic review of assessment and treatment of moderate to severe Alzheimer's disease.Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.Clinically tested drugs for Alzheimer's disease.Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease.NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease.Galantamine versus donepezil in Chinese patients with Alzheimer's disease: results from a randomized, double-blind study.Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.Current experimental therapy for Alzheimer's diseaseTreatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population: a 52-week prospective study.Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.An update on the pharmacology of galantamine.Galantamine in Alzheimer's disease.Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis.Donepezil delays progression to AD in MCI subjects with depressive symptoms.DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCTHave last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review.Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled studyAre the available apathy measures reliable and valid? A review of the psychometric evidenceEffects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease.Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease.Systematic Review of Sex-Specific Reporting of Data: Cholinesterase Inhibitor Example.Combination benefit of cognitive rehabilitation plus donepezil for Alzheimer's disease patients.Clock drawing and frontal lobe behavioral effects of memantine in Alzheimer's disease: a rater-blinded study.Drug therapy for Alzheimer's disease.Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease.
P2860
Q24244773-024D8092-9DCA-4099-8FD6-20F67E727B46Q24246158-8E63D8F9-2A78-4D69-8B75-1636804B30CDQ24800530-2218690E-1568-456A-84D8-52F8EE70DEA6Q26863383-50C7B3BB-48E9-4F06-AED8-2342C41FF5A2Q30443975-EE1C257D-585F-4D35-A6B0-61789DAD41D1Q30874688-1F56B134-82CE-4B04-9298-B130F5E4CF70Q33210272-4C663909-9FD3-4F37-9E6E-BC5A199A2CB4Q33790288-F6184D0D-880C-49E2-8B4A-9699CE128D74Q33795194-B58F878C-1448-4D04-912C-9303277FFF4AQ33912750-E33FD849-DFAF-44A3-BCEA-0AD0D2CE0CC7Q34123013-C55FF375-64D0-4070-9006-8C4E30FD9B94Q34552380-7014A694-8F35-4116-92C2-C8DC34498665Q34648742-F58D124D-B6FA-4D6C-8931-5B07913C2D02Q34655353-F3377AD8-1561-4638-A2B8-1081B53445A9Q34977044-DD6E02D7-4976-410A-ABFA-41BF3B1FB24CQ34987695-D38A9565-A525-4EF1-B195-3F6B7403C3A5Q35164747-AA874B37-EFE0-4F94-90DC-95F9EC734B53Q35748293-5895738D-1976-4B88-874A-D899450B1108Q36310524-C53C5B00-357F-4442-A610-AABAB0C9547BQ36456009-00549A64-53F6-4830-992C-8D90159187AFQ36513610-8F7B7917-61CD-4173-A447-E754B16BB8EFQ36731881-D3A19B14-DBCE-4D6B-AC59-C8303B676161Q36742405-4F37C08F-6B96-4184-B6C2-5ED026A2501AQ36854444-10338F3E-06BA-49C1-83D8-23A4C51E879EQ36897422-FF490805-3696-4259-B448-D9D16E3557FFQ37016107-1A997B1C-A8B9-4322-8640-C2337F45260EQ37035226-FA971240-8735-45C6-9D4E-8D75E5DE416DQ37193026-1693A3B9-8868-4279-9B47-29D478D341F8Q37231378-F9FB92D8-834A-46D9-9CE1-F6A256962107Q37295359-CF20A12D-48EE-47CA-9314-46372A905F4BQ37396299-7D91A880-4C2D-4A68-B069-E1F45985313FQ37417244-913360F4-0643-452F-9FCB-985CF5AB23CCQ37518104-17D8D23D-DC3E-4DE7-98AC-BC9FC7A1919FQ37607844-96083ABF-BD39-4DEF-B429-A94D4D551EDFQ37695074-0ABB15BE-3211-498E-859E-4C6B39E091D6Q38612393-1BC66CCB-6BE6-4E23-AFF9-BBAF7473AA37Q41471873-1AC6833E-79F3-4D56-9032-91A5E811985DQ42610768-4A4E1AF8-F17F-4E3E-839A-AC6418A71ECDQ42614495-1937F843-0F16-4AFD-8F5A-2B337397F790Q43099284-F609ACA2-7DD9-4FCF-A718-FEB60B6EC536
P2860
Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Effects of a flexible galantam ...... a randomised, controlled trial
@ast
Effects of a flexible galantam ...... a randomised, controlled trial
@en
Effects of a flexible galantam ...... a randomised, controlled trial
@nl
type
label
Effects of a flexible galantam ...... a randomised, controlled trial
@ast
Effects of a flexible galantam ...... a randomised, controlled trial
@en
Effects of a flexible galantam ...... a randomised, controlled trial
@nl
prefLabel
Effects of a flexible galantam ...... a randomised, controlled trial
@ast
Effects of a flexible galantam ...... a randomised, controlled trial
@en
Effects of a flexible galantam ...... a randomised, controlled trial
@nl
P2093
P2860
P3181
P356
P1476
Effects of a flexible galantam ...... a randomised, controlled trial
@en
P2093
P2860
P304
P3181
P356
10.1136/JNNP.71.5.589
P407
P577
2001-11-01T00:00:00Z